EUVIMEDEUVIMED entdecken
Übersichtsarbeit

DPYD Genotyping and Predicting Fluoropyrimidine Toxicity: Where do we Stand?

Lucija Lešnjaković, Lana Ganoci iD, Ivan Bilić, Livija Šimičević iD, Iva Mucalo iD, Stjepko Pleština, Nada Božina iD

Pharmacogenomics · 2023

DOI: 10.2217/pgs-2022-0135 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacogenomics, 2023. Verfasst von Lucija Lešnjaković und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia. Hauptthemen laut MEDLINE: Antimetabolites, Antineoplastic, Dihydropyrimidine Dehydrogenase Deficiency, Dihydrouracil Dehydrogenase (NADP), Fluorouracil. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 79 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fluoropyrimidines (FPs) are antineoplastic drugs widely used in the treatment of various solid tumors. Nearly 30% of patients treated with FP chemotherapy experience severe FP-related toxicity, and in some cases, toxicity can be fatal. Patients with reduced activity of DPD, the main enzyme responsible for the breakdown of FP, are at an increased risk of experiencing severe FP-related toxicity. While European regulatory agencies and clinical societies recommend pre-treatment DPD deficiency screening for patients starting treatment with FPs, this is not the case with American ones. Pharmacogenomic guidelines issued by several pharmacogenetic organizations worldwide recommend testing four DPD gene (DPYD) risk variants, but these can predict only a proportion of toxicity cases. New evidence on additional common DPYD polymorphisms, as well as identification and functional characterization of rare DPYD variants, could partially address the missing heritability of DPD deficiency and FP-related toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antimetabolites, AntineoplasticDihydropyrimidine Dehydrogenase DeficiencyDihydrouracil Dehydrogenase (NADP)FluorouracilPharmacogenomic VariantsHumansCapecitabineGenotype

Stichwörter der Autor:innen

DPYDadverse drug reactionschemotherapydihydropyrimidine dehydrogenasefluoropyrimidine toxicityfluoropyrimidinesfluorouracilpharmacogenetics

Substanzen

Antimetabolites, AntineoplasticCapecitabineDihydrouracil Dehydrogenase (NADP)Fluorouracil

Autor:innen und Institutionen

  • Department of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia.
  • Division of Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia.
  • School of Medicine, University of Zagreb, Zagreb, Croatia.
  • Centre for Applied Pharmacy, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia.
  • Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia.

ORCID-Profile: Lana Ganoci, Livija Šimičević, Iva Mucalo, Nada Božina

Zitieren

APA

Lešnjaković, L., Ganoci, L., Bilić, I., Šimičević, L., Mucalo, I., Pleština, S., & Božina, N. (2023). DPYD Genotyping and Predicting Fluoropyrimidine Toxicity: Where do we Stand?. Pharmacogenomics. https://doi.org/10.2217/pgs-2022-0135

Vancouver

Lešnjaković L, Ganoci L, Bilić I, Šimičević L, Mucalo I, Pleština S, et al. DPYD Genotyping and Predicting Fluoropyrimidine Toxicity: Where do we Stand?. Pharmacogenomics. 2023. doi:10.2217/pgs-2022-0135

BibTeX
@article{Lenjakovi2023,
  author = {Lešnjaković, Lucija and Ganoci, Lana and Bilić, Ivan and Šimičević, Livija and Mucalo, Iva and Pleština, Stjepko and Božina, Nada},
  title = {DPYD Genotyping and Predicting Fluoropyrimidine Toxicity: Where do we Stand?},
  journal = {Pharmacogenomics},
  year = {2023},
  doi = {10.2217/pgs-2022-0135}
}
Kostenlos starten →